Alzamend Neuro (ALZN) Non-Current Assets (2022 - 2026)
Alzamend Neuro's (ALZN) quarterly Non-Current Assets came in at $314866.0 in Q2 2026, down 26.02% year-over-year from $425606.0 in Q2 2025, and down 8.08% quarter-over-quarter from $342551.0 in Q1 2026.
Powered by 
Analysis
Alzamend Neuro (ALZN) Non-Current Assets (2022 - 2026) Analysis & Trends
Alzamend Neuro has disclosed Non-Current Assets across 5 years of filings, most recently posting $314866.0 for Q2 2026.
- In Q2 2026, Non-Current Assets fell 26.02% year-over-year to $314866.0; the TTM figure through Apr 2026 stood at $1.4 million (up 24.12% YoY), while the FY2026 annual figure was $314866.0, down 26.02% from the prior year.
- Non-Current Assets came in at $314866.0 for Q2 2026 at Alzamend Neuro, down from $342551.0 in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $425606.0 in Q2 2025 to a low of $79843.0 in Q2 2023.
- Average Non-Current Assets over 5 years is $224107.1, with a median of $214401.0 recorded in 2023.
- Year-over-year, Non-Current Assets surged 141.35% in 2025 and fell 26.02% in 2026.
- Over 5 years, Non-Current Assets stood at $90489.0 in 2022, then jumped by 122.92% to $201716.0 in 2023, then grew by 19.46% to $240976.0 in 2024, then surged by 53.64% to $370236.0 in 2025, then declined by 14.96% to $314866.0 in 2026.
- Per Business Quant data, the three most recent Non-Current Assets figures were $314866.0 in Q2 2026, $342551.0 in Q1 2026, and $370236.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 207.31 Bn | 193.32 Bn | 7.24 Bn | 60.68 Bn |
| 2 | Gilead Sciences | 179.04 Bn | 175.86 Bn | 6.22 Bn | 35.42 Bn |
| 3 | Vertex Pharmaceuticals | 131.34 Bn | 123.48 Bn | 2.84 Bn | 14.88 Bn |
| 4 | Regeneron Pharmaceuticals | 81.84 Bn | 73.85 Bn | 3.93 Bn | 23.28 Bn |
| 5 | Argenx Se | 61.21 Bn | 56.03 Bn | 1.37 Bn | 1.96 Bn |
| 6 | Moderna | 53.12 Bn | 47.98 Bn | 52.00 Mn | 5.15 Bn |
| 7 | Alnylam Pharmaceuticals | 33.32 Bn | 30.02 Bn | 992.69 Mn | 938.60 Mn |
| 8 | Biogen | 31.66 Bn | 30.38 Bn | 1.96 Bn | 24.78 Bn |
| 9 | Roivant Sciences | 29.36 Bn | 29.36 Bn | 1.16 Mn | 564.41 Mn |
| 10 | Alzamend Neuro | 5.57 Mn | 5.57 Mn | - | 314,866.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Apr 30, 2026 | 314,866.00 |
| Jan 31, 2026 | 342,551.00 |
| Oct 31, 2025 | 370,236.00 |
| Jul 31, 2025 | 397,921.00 |
| Apr 30, 2025 | 425,606.00 |
| Jan 31, 2025 | 228,291.00 |
| Oct 31, 2024 | 240,976.00 |
| Jul 31, 2024 | 253,661.00 |
| Apr 30, 2024 | 176,346.00 |
| Jan 31, 2024 | 189,031.00 |
| Oct 31, 2023 | 201,716.00 |
| Jul 31, 2023 | 214,401.00 |
| Apr 30, 2023 | 79,843.00 |
| Jan 31, 2023 | 85,166.00 |
| Oct 31, 2022 | 90,489.00 |
| Jul 31, 2022 | 95,812.00 |
| Apr 30, 2022 | 102,909.00 |